Lifeboat Foundation

Researchers at the University of Alabama at Birmingham, and Southern Research, have identified a new drug candidate that they claim could represent a “distinct and innovative” approach to treating type 1 and type 2 diabetes. The small molecule drug, designated SRI-37330, inhibits the expression of a protein known as TXNIP—which the team had previously identified as a top glucose-induced gene—in both mouse and human islets.nnResults from the researchers’ preclinical studies suggested that SRI-37330 acts on pancreatic islet cells that produce glucagon and insulin, and also acts on the liver. The findings showed that the drug could have therapeutic effects against diabetes, in both lean and obese individuals. Tests on isolated human and mouse pancreatic islets, on mouse and rat cell cultures, and in animal models of both type 1 and type 2 diabetes, demonstrated that SRI-37330 improved diabetes-related hyperglycemia, and hyperglucagonemia; reduced the excessive production of glucose by the liver; and reduced fatty liver, or hepatic steatosis.nn

Studies showed non-toxic, orally bioavailable small molecule effectively rescued mice from models of type 1 and type 2 diabetes, and reduced fatty liver.

Tesla and CureVac have collaborated on a patent for an RNA bioreactor.

Although there are no human vaccines made with RNA, the technology could break through on COVID-19 (coronavirus).

The bioreactor works by combining chemical agents in an egg-shaped magnetic mixer.

Continue reading “Tesla Has Been Working On an RNA Bioreactor” »

A study published in BMC Cancer analyzed the relationship between education level and survival in multiple myeloma and observed that patients with lower education levels may have lower survival rates.

A study observed that multiple myeloma patients with lower education levels may have lower survival rates compared to those with higher education levels.

Before the first oncogene mutations were discovered in human cancer in the early 1980s, the 1970s provided the first data suggesting alterations in the genetic material of tumors. In this context, the prestigious journal Nature published in 1975 the existence of a specific alteration in the transformed cell: an RNA responsible for carrying an amino acid to build proteins (transfer RNA) was missing a piece, the enigmatic nucleotide ‘Y.’

After that outstanding observation, virtually no developments were made for forty-five years on the causes and consequences of not having the correct base in RNA.

In an article published in Proceedings of the National Academy of Sciences (PNAS) by the group of Dr. Manel Esteller, Director of the Josep Carreras Leukaemia Research Institute, ICREA Research Professor and Professor of Genetics at the University of Barcelona has solved this mystery by observing that in cancer cells the protein that generates the nucleotide Y is epigenetically inactivated, causing small but highly aggressive tumors.

Populations of vampire bats are exploding and spreading deadly diseases.

Check out VICE News for more: http://vicenews.com
Follow VICE News here:
Facebook: https://www.facebook.com/vicenews
Twitter: https://twitter.com/vicenews
Tumblr: http://vicenews.tumblr.com/
Instagram: http://instagram.com/vicenews
More videos from the VICE network: https://www.fb.com/vicevideo

As one of the leaders in developing a COVID-19 vaccine, Moderna signed a contract worth up to $1.525 billion with the U.S. government to supply 100 million doses of mRNA-1273, the company’s experimental COVID-19 vaccine.

The agreement also includes incentive payments for hitting a production schedule. Moderna had a previous award of up to $955 million from BARDA for the development of the vaccine to licensure, which brings the U.S. government’s commitment for early access to the vaccine up to $2.48 billion. The U.S. government, as part of Operation Warp Speed, also can acquire another 400 million doses.

As part of this deal, the U.S. government says Americans will receive the vaccine at no cost. It is possible that healthcare professionals will charge for the cost of administering it.

Kate Broderick discusses the development of INOVIO’s frontrunner COVID-19 DNA vaccine and states the need for preparedness for future outbreaks.

The Space Force’s announcement last week that United Launch Alliance and SpaceX will launch expensive spy satellites and other military payloads brings a long and often fierce battle for government funds to an end — at least for now.

Why it matters: This type of government money — particularly in light of the economic downturn caused by the coronavirus pandemic — is key for space companies that often work on thin margins.

The state of play: ULA was awarded the bulk of the funds — $337 million — for two missions due to launch in 2022, with SpaceX winning $316 million for one mission launching that year.

(Credit: Anne Marthe Widvey/Flickr)

The finding may potentially make it easier to monitor people with sleep disorders, as well as unconscious coma patients or those under anesthesia.